AAN 2026 18 - 22 April 2026

Semaglutide Impacts Proteomic Signatures Related to Dementia Risk in the SELECT Cardiovascular Outcomes Trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Neurodegenerative diseases
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)